These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20374002)

  • 21. [Immunological evaluation of vector-expressed M2 and HA genes of H5N1 influenza virus in mice].
    Guo J; Yao L; Chen A; Xu Y; Liu X; Shu Y; Zhang Z
    Sheng Wu Gong Cheng Xue Bao; 2010 May; 26(5):649-56. PubMed ID: 20684310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus.
    Niqueux E; Guionie O; Amelot M; Jestin V
    Vaccine; 2013 Aug; 31(38):4121-8. PubMed ID: 23845804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector.
    Jiang Y; Yu K; Zhang H; Zhang P; Li C; Tian G; Li Y; Wang X; Ge J; Bu Z; Chen H
    Antiviral Res; 2007 Sep; 75(3):234-41. PubMed ID: 17451817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and use of fowlpox vectored vaccines for avian influenza.
    Bublot M; Pritchard N; Swayne DE; Selleck P; Karaca K; Suarez DL; Audonnet JC; Mickle TR
    Ann N Y Acad Sci; 2006 Oct; 1081():193-201. PubMed ID: 17135511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin.
    Wang G; Zhou F; Buchy P; Zuo T; Hu H; Liu J; Song Y; Ding H; Tsai C; Chen Z; Zhang L; Deubel V; Zhou P
    J Infect Dis; 2014 Mar; 209(5):676-85. PubMed ID: 23911711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.
    Giles BM; Crevar CJ; Carter DM; Bissel SJ; Schultz-Cherry S; Wiley CA; Ross TM
    J Infect Dis; 2012 May; 205(10):1562-70. PubMed ID: 22448011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
    Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
    J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens.
    Wu Q; Fang L; Wu X; Li B; Luo R; Yu Z; Jin M; Chen H; Xiao S
    Mol Immunol; 2009 Jul; 46(11-12):2210-7. PubMed ID: 19446339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
    Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP
    Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved immune responses against avian influenza virus following oral vaccination of chickens with HA DNA vaccine using attenuated Salmonella typhimurium as carrier.
    Jazayeri SD; Ideris A; Zakaria Z; Yeap SK; Omar AR
    Comp Immunol Microbiol Infect Dis; 2012 Sep; 35(5):417-27. PubMed ID: 22512819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the immune response to recombinant DNA vaccine and adenoviral vaccine co-expressing the M1 and HA genes of H5N1 influenza virus in mice.
    Guo J; Yao L; Chen A; Liu X; Fu J; Xu P; Zhang Z
    Sheng Wu Gong Cheng Xue Bao; 2011 Jun; 27(6):876-83. PubMed ID: 22034816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A subunit vaccine candidate derived from a classic H5N1 avian influenza virus in China protects fowls and BALB/c mice from lethal challenge.
    Liu G; Zhang F; Shi J; Tian G; Chen H; Yu K; Meng Q
    Vaccine; 2013 Nov; 31(46):5398-404. PubMed ID: 24055355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.